Spirometry for Afrezza

You may have read or heard about a new form of insulin that is inhaled through the mouth into the lungs instead of injected. The availability of inhalable insulin is long-awaited news for people with diabetes. In June 2014 the FDA approved Afrezza®, a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Because of the effect of Afrezza® on pulmonary function, all patients must have spirometry assessed prior to initiating therapy and regularly thereafter.

Because this is a new indication for spirometry testing there are a lot of questions about spirometer selection, staff training, and reimbursement. The spirometry testing requirements for Afrezza® not only include initial qualification but indefinite monitoring; consequently, purchasing a spirometer that is easy, accurate, maintenance-free, and reimbursable should be a priority.

 

We're here to help.
Spirometry should be easy and seamlessly integrate into your workflow

Utilizing the resources below will help guide your spirometer selection, streamline your testing & tracking, and clarify coding & reimbursement specific to the screening of Afrezza® patients. For assistance, contact us today via email or at 1-630-571-1980



The following is general information in regard to the required use of spirometry for Afrezza® patient selection and follow up monitoring. Full Prescribing Information can and should be obtained by contacting Mannkind Corporation.

Prior to initiating Afrezza® therapy:

Afrezza® is contraindicated in patients with chronic lung disease such as asthma or COPD because of the risk of acute bronchospasm in these patients. Before initiating Afrezza®, perform a medical history, physical examination and spirometry (FEV1) in all patients to identify potential lung disease.

The safety and efficacy of Afrezza® in patients who smoke has not been established. The use of Afrezza® is not recommended in patients who smoke or who have recently stopped smoking.

Afrezza® has not been studied in patients younger than 18 years of age.

After initiating Afrezza® therapy:

In addition to acquiring baseline spirometry, repeat spirometry after the first 6 months of therapy and annually thereafter, even in the absence of pulmonary symptoms. In patients who have a decline of > 20% in FEV1 from baseline, consider discontinuing Afrezza®. Consider more frequent monitoring of pulmonary function in patients with pulmonary symptoms such as wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough.

Pharmaceutical Companies Contact Us to see how we help pharma companies meet their marketing and educational objectives.

Contact Jones